SLNO•businesswire•
SLNO Investors: Contact Kirby McInerney LLP About Investigation into Soleno Therapeutics, Inc.
Summary
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On August 15, 2025, Scorpion Capital published a report that described Soleno’s only product, Vykat XR, as ov
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 12, 2026 by businesswire